{"denoms":[{"counts":[{"groupId":"BG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or PET-CT scan and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT and/or PET-CT scan\n\nElimusertib: Given PO\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET-CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nStereotactic Body Radiation Therapy: Undergo SBRT","id":"BG000","title":"Treatment (Pembrolizumab, BAY 1895344, SBRT)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"63","upperLimit":"92","value":"67"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"ECOG = 0"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"ECOG = 1"}]}],"description":"0 - Fully active, able to carry on all pre-disease performance without restriction\n\n1. \\- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature\n2. \\- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours\n3. \\- Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours\n4. \\- Completely disabled; cannot carry on any selfcare; totally confined to bed or chair\n5. \\- Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"2 prior lines of therapy"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"3 prior lines of therapy"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"4 prior lines of therapy"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number Lines of Prior Therapy","unitOfMeasure":"Participants"}],"populationDescription":"All enrolled patients"}